한빛사 논문
Prof Sung Hoon Noh MD a,*, Sook Ryun Park MDb, Prof Han-Kwang Yang MDc, Prof Hyun Cheol Chung MDd, Prof Ik-Joo Chung MD e, Prof Sang-Woon Kim MD f, Hyung-Ho Kim MD g, Prof Jin-Hyuk Choi MDh, Prof Hoon-Kyo Kim MD i, Prof Wansik Yu MD j, Jong Inn Lee MD k, Prof Dong Bok Shin MD l, Prof Jiafu Ji MD m, Jen-Shi Chen MD n, Yunni Lim MS o, Stella Ha MS o, Prof Yung-Jue Bang PhDp *, on behalf of the CLASSIC trial investigators†
a Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea
b Gastric Cancer Branch, Research Institute and Hospital, National Cancer Center, Goyang, South Korea
c Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea
d Department of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
e Department of Internal Medicine, Chonnam National University Hwasun Hospital, Jeonnam, South Korea
f Department of Surgery, Yeungnam University College of Medicine, Daegu, South Korea
g Department of Surgery, Seoul National University Bundang Hospital, Seongnam, South Korea
h Department of Hematology-Oncology, Ajou University Hospital, Suwon, South Korea
i Department of Internal Medicine, St Vincent's Hospital, Suwon, South Korea
j Department of Surgery, Kyungpook National University Medical Center, Daegu, South Korea
k Department of Surgery, Korea Institute of Radiological and Medical Sciences, Korea Cancer Center, Seoul, South Korea
l Department of Hematology-Oncology, Gachon University Gil Medical Center, Incheon, South Korea
m Beijing Cancer Hospital, Beijing, China
n Department of Internal Medicine, Chang Gung Memorial Hospital and Chang Gung University Taipei, Taoyuan, Taiwan
o Clinical Research Division, Roche Korea, Seoul, South Korea
p Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea
* Contributed equally
† For a complete list of the CLASSIC trial investigators see appendix
Correspondence to: Prof Sung Hoon Noh, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-Ro, Seodeamungyu, Seoul, 120-752, South Korea
Abstract
Background
The CLASSIC trial was done to compare adjuvant capecitabine plus oxaliplatin versus observation after D2 gastrectomy for patients with stage II or III gastric cancer. The planned interim analysis of CLASSIC (median follow-up 34 months) showed that adjuvant capecitabine plus oxaliplatin significantly improved disease-free survival, the primary endpoint, compared with observation after D2 gastrectomy. We report the 5-year follow-up data from the trial.
Methods
CLASSIC was a phase 3, randomised, open-label study done at 35 cancer centres, medical centres, and hospitals in China, South Korea, and Taiwan. Patients with stage II?IIIB gastric cancer who underwent curative D2 gastrectomy were randomly assigned (1:1) after surgery to receive adjuvant chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m2 twice daily on days 1?14 plus intravenous oxaliplatin 130 mg/m2 on day 1) for 6 months or observation alone. Randomisation was stratified by country and disease stage with a permuted block (size four) design. Neither patients nor investigators were masked to treatment assignment. The primary outcome was 3-year disease-free survival in the intention-to-treat population. This analysis presents the final preplanned assessment of outcomes after 5 years. The study is registered with ClinicalTrials.gov, NCT00411229.
Findings
We enrolled 1035 patients: 520 were randomly assigned to adjuvant capecitabine and oxaliplatin, and 515 to observation. Median follow-up for this analysis in the intention-to-treat population was 62·4 months (IQR 54-70). 139 (27%) patients had disease-free survival events in the adjuvant capecitabine and oxaliplatin group versus 203 (39%) patients in the observation group (stratified hazard ratio [HR] 0·58, 95% CI 0·47-0·72; p<0·0001). Estimated 5-year disease-free survival was 68% (95% CI 63-73) in the adjuvant capecitabine and oxaliplatin group versus 53% (47-58) in the observation alone group. By the clinical cutoff date, 103 patients (20%) had died in the adjuvant capecitabine and oxaliplatin group versus 141 patients (27%) in the observation group (stratified HR 0·66, 95% CI 0·51-0·85; p=0·0015). Estimated 5-year overall survival was 78% (95% CI 74-82) in the adjuvant capecitabine and oxaliplatin group versus 69% (64-73) in the observation group. Adverse event data were not collected after the primary analysis.
Interpretation
Adjuvant treatment with capecitabine plus oxaliplatin after D2 gastrectomy should be considered for patients with operable stage II or III gastric cancer.
Funding
F Hoffmann La-Roche and Sanofi.
논문정보
관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기